RUNX-fusion Target Genes in Normal and Leukemic Hematopoiesis
正常和白血病造血中的 RUNX 融合靶基因
基本信息
- 批准号:7033500
- 负责人:
- 金额:$ 15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-01 至 2008-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): RUNX1/CBFbeta is a key regulator of normal hematopoiesis that is frequently involved in leukemia. Rearrangements involving the CBF family account for approximately 25% of de novo myeloid leukemias and 22% of pediatric lymphoblastic leukemias. The overall objective of the proposed study is to understand gene expression that is determined by leukemia-associated translocation fusion proteins of the RUNX1/CBFbeta transcription factor, and to evaluate the role of these regulated genes in normal and leukemic stem cell self-renewal, survival and differentiation. The fusion proteins we will focus on are the t(8;21) encoding AML1-ETO, t(3;21) encoding AML1-EVI1, and the inv16/t(16;16) encoding CBFbeta- MYH11. These will be expressed in human HSPC by lentiviral transduction. Controls will include a lentivirus lacking a transgene as well as a lentivirus expressing RUNX1. Differentially expressed target genes will be validated using human HSPC expressing either AML1-ETO or CBFp-MYH11 that have acquired enhanced self-renewal properties due to the oncogene expression. Clinical samples from AML patients expressing a RUNX-fusion oncogene will also be analyzed for expression of the identified genes (Aim 1). The specific contribution of identified target genes to HSPC function will be evaluated by over-expressing genes that are repressed by the fusion proteins, and conversely by knocking-down those genes that become upregulated upon fusion protein expression, using lentiviral transduction of the human HSPC that express these oncogenes and that self-renew in vitro. Primary human HSPC will be similarly transduced to determine the contribution of the targeted gene to normal stem cell function (Aim 2). Understanding the modulation of the self-renewal process by these fusion proteins could give insight into the normal mechanisms of self-renewal employed by the stem cell.
描述(申请人提供):RUNX1/CBFbeta是正常造血的关键调节因子,经常与白血病有关。涉及CBF家族的重排约占新发髓系白血病的25%,占儿童淋巴母细胞性白血病的22%。本研究的总体目标是了解由RUNX1/CBFβ转录因子的白血病相关易位融合蛋白决定的基因表达,并评估这些调控基因在正常和白血病干细胞自我更新、存活和分化中的作用。我们将关注的融合蛋白是编码AML1-ETO的t(8;21),编码AML1-EVI1的t(3;21),以及编码CBFbeta-MYH11的inv16/t(16;16)。这些基因将通过慢病毒转导在人HSPC中表达。对照包括缺乏转基因的慢病毒和表达RUNX1的慢病毒。差异表达的靶基因将使用表达AML1-ETO或CBFp-MYH11的人HSPC进行验证,这些HSPC由于癌基因的表达而获得了增强的自我更新特性。表达RUNX融合癌基因的AML患者的临床样本也将被分析识别的基因的表达(目标1)。识别的靶基因对HSPC功能的具体贡献将通过过度表达被融合蛋白抑制的基因来评估,反之,通过慢病毒转导表达这些癌基因并在体外自我更新的人HSPC,通过敲除那些融合蛋白表达上调的基因来评估。原代人类HSPC将进行类似的转导,以确定目标基因对正常干细胞功能的贡献(目标2)。了解这些融合蛋白对自我更新过程的调节,可以深入了解干细胞使用的自我更新的正常机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES C MULLOY其他文献
JAMES C MULLOY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES C MULLOY', 18)}}的其他基金
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
MLL 融合蛋白在谱系确定和白血病发生中的指导作用
- 批准号:
9290731 - 财政年份:2017
- 资助金额:
$ 15万 - 项目类别:
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
MLL 融合蛋白在谱系确定和白血病发生中的指导作用
- 批准号:
10115634 - 财政年份:2017
- 资助金额:
$ 15万 - 项目类别:
Leukemia stem cell polarity and differentiation therapy
白血病干细胞极性与分化治疗
- 批准号:
10227111 - 财政年份:2017
- 资助金额:
$ 15万 - 项目类别:
The Role of MLL-AF9 in Acute Myeloid Leukemia
MLL-AF9 在急性髓系白血病中的作用
- 批准号:
7698026 - 财政年份:2009
- 资助金额:
$ 15万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 15万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
- 批准号:
10762827 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别: